A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMpower210
- Sponsors Roche
- 21 Jul 2017 Planned End Date changed from 31 May 2019 to 30 Apr 2019.
- 21 Jul 2017 Planned primary completion date changed from 31 May 2019 to 30 Apr 2019.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.